COSCIENS Biopharma Inc. (CSCID)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

-4M 0 4M 8M 12M Q1 '21: 1.7M Q2 '21: 1.6M Q3 '21: 1.1M Q4 '21: 956K Q1 '22: 1.5M Q2 '22: -222K Q3 '22: 1.9M Q4 '22: 11.4M Q1 '23: 2.1M Q2 '23: 1.4M Q3 '23: 2M Q4 '23: 1.2M Q1 '24: 2.1M Q2 '24: 2.3M Q3 '24: 1.9M Q4 '24: 3.3M Q1 '25: 1.5M Q2 '25: 2.7M Q3 '25: 1.5M Q4 '25: 1.8M Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Gross Profit Quarterly

-700K 0 700K 1.4M 2.1M Q2 '18: -29K Q3 '18: 169K Q4 '18: -21K Q2 '19: 93K Q3 '19: 283K Q1 '23: 1.2M Q2 '23: 797K Q3 '23: 805K Q4 '23: 148K Q1 '24: 904K Q2 '24: 819K Q3 '24: 957K Q4 '24: 2M Q1 '25: 443K Q2 '25: 974K Q3 '25: 621K Q4 '25: 609K Q3 '18 Q3 '19 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Operating Income Quarterly

-7.5M -5M -2.5M 0 2.5M 5M 7.5M Q4 '20: -1.2M Q1 '21: -1.3M Q2 '21: -2.2M Q3 '21: -2.1M Q4 '21: -3.1M Q1 '22: -2.8M Q2 '22: -4.7M Q3 '22: -3.7M Q1 '23: -4.2M Q2 '23: -1.1M Q3 '23: -1.1M Q4 '23: -2M Q1 '24: -1.8M Q2 '24: -3.8M Q3 '24: -6.3M Q4 '24: -6.4M Q1 '25: -3.6M Q2 '25: -2.4M Q3 '25: -2.3M Q4 '25: -2.4M Q1 '21 Q4 '21 Q3 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Net Income Quarterly

-7.5M -5M -2.5M 0 2.5M 5M 7.5M Q4 '20: -1.3M Q1 '21: -1.5M Q2 '21: -2.1M Q3 '21: -1.9M Q4 '21: -2.9M Q1 '22: -2.6M Q2 '22: -4.2M Q3 '22: -3.4M Q1 '23: -4.3M Q2 '23: -860K Q3 '23: -776K Q4 '23: 2.4M Q1 '24: -1.4M Q2 '24: -1.4M Q3 '24: -5.8M Q4 '24: -6.7M Q1 '25: -3.7M Q2 '25: -2.7M Q3 '25: -1.8M Q4 '25: -2.2M Q1 '21 Q4 '21 Q3 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Cost of Revenue Quarterly

0 2.5M 5M 7.5M Q1 '21: 29K Q2 '21: 12K Q3 '21: 31K Q4 '21: 18K Q1 '22: 79K Q2 '22: 13K Q3 '22: 14K Q4 '22: 5.9M Q1 '23: 17K Q2 '23: 595K Q3 '23: 1.1M Q4 '23: 1.1M Q1 '24: 1.2M Q2 '24: 1.5M Q3 '24: 914K Q4 '24: 1.3M Q1 '25: 1.1M Q2 '25: 1.8M Q3 '25: 862K Q4 '25: 1.2M Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Operating Cash Flow Quarterly

-12M -6M 0 6M 12M 18M Q1 '21: -1M Q2 '21: -3.6M Q3 '21: -1.5M Q4 '21: -2.4M Q1 '22: -1.5M Q2 '22: -4.8M Q3 '22: -3.9M Q4 '22: 15.5M Q1 '23: -4.1M Q2 '23: -813K Q3 '23: 144K Q4 '23: 2.1M Q1 '24: -2.4M Q2 '24: -1.4M Q3 '24: -7.8M Q4 '24: -3M Q1 '25: -1.9M Q2 '25: -4.4M Q3 '25: -676K Q4 '25: -1.5M Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Free Cash Flow Quarterly

-12M -6M 0 6M 12M 18M Q1 '21: -1.1M Q2 '21: -3.6M Q3 '21: -1.5M Q4 '21: -2.4M Q1 '22: -1.5M Q2 '22: -4.9M Q3 '22: -4M Q4 '22: 15.2M Q1 '23: -4.1M Q2 '23: -867K Q3 '23: 94K Q4 '23: 1.6M Q1 '24: -2.9M Q2 '24: -1.5M Q3 '24: -7.9M Q4 '24: -3.3M Q1 '25: -2.5M Q2 '25: -4.5M Q3 '25: -680K Q4 '25: -1.5M Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q2 '19: 17.3M Q3 '19: 16.9M Q1 '20: 21.9M Q2 '20: 23.5M Q3 '20: 56.2M Q1 '21: 95.4M Q2 '21: 4.8M Q3 '21: 4.9M Q1 '22: 121.4M Q2 '22: 4.9M Q3 '22: 4.9M Q1 '23: 1.2M Q2 '23: 1.8M Q3 '23: 1.8M Q1 '24: 1.8M Q2 '24: 2.2M Q3 '24: 3.1M Q1 '25: 3.1M Q2 '25: 3.2M Q3 '25: 3.2M Q3 '19 Q3 '20 Q3 '21 Q3 '22 Q3 '23 Q3 '24 Q3 '25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q4 '19: -0.35 Q1 '20: -0.01 Q2 '20: -0.17 Q3 '20: -0.17 Q4 '20: -3.13 Q1 '21: -3.19 Q2 '21: -3.47 Q3 '21: -3.05 Q4 '21: -0.66 Q1 '22: -0.66 Q2 '22: -1.10 Q3 '22: -2.20 Q4 '24: -5.60 Q1 '25: -6.00 Q2 '25: -6.21 Q3 '25: -4.93 Q4 '25: -3.26 Q1 '20 Q4 '20 Q3 '21 Q2 '22 Q1 '25 Q4 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.